ArticleFrontiers in medicine2025
Prevalence and clinical relevance of sarcopenia in Chinese patients with porto-sinusoidal vascular disorder.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Porto-sinusoidal vascular disorder (PSVD) is a rare vascular liver disease that has similar manifestations to liver cirrhosis. However, limited information is available on the prevalence and clinical impacts of sarcopenia in patients with PSVD in China. Methods: We enrolled 92 patients with PSVD from West China Hospital between January 2019 to June 2024 to analyze and characterize the burden of sarcopenia. The psoas muscle mass index (PMI), measured at the third lumbar vertebra (L3-PMI, cm Results: Sarcopenia was observed in 17 out of the 92 PSVD patients (18.5%). The sarcopenia group had a higher proportion of patients with a history of esophagogastric variceal bleeding (EGVB) compared to the non-sarcopenia group (88.24% vs. 60.0%, Conclusion: Sarcopenia is common in patients with PSVD, particularly among those with a history of EGVB. TIPS placement may potentially enhance the muscle mass of PSVD patients. Importantly, sarcopenia appears to negatively impact clinical outcomes in PSVD patients undergoing endoscopic therapy for variceal bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.